Amicus Therapeutics Inc. (NASDAQ:FOLD) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET

Company Participants

Bradley Campbell - President, Chief Executive Officer

Sébastien Martel - Chief Business Officer

Jeff Castelli - Chief Development Officer

Daphne Quimi - Chief Financial Officer

Andrew Faughnan - Executive Director, Investor Relations

Conference Call Participants

Ritu Baral - Cowen

Anupam Rama - JP Morgan

Joseph Schwartz - SVB Securities

Tazeen Ahmad - Bank of America

Sarah - UBS

Dae Gon Ha - Stifel

Salveen Richter - Goldman Sachs

Yun Zhong - BTIG

Gil Blum - Needham & Co.

Operator

Good morning ladies and gentlemen and welcome to the Amicus Therapeutics third quarter 2022 financial results conference call and webcast. At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Executive Director of Investor Relations. You may begin.

Andrew Faughnan

Thank you Shannon. Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics third quarter 2022 financial results and corporate highlights. Leading today’s call we have Bradley Campbell, President and Chief Executive Officer; Daphne Quimi, Chief Financial Officer; Sébastien Martel, Chief Business Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer, and Ellen Rosenberg, Chief Legal Officer.

As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved. Any or all of the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make, or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date hereof. All forward-looking statements are qualified in their entirety this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect or circumstances after the date hereof.

For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factors section of our quarterly report on Form 10-Q for the quarter ended September 30, 2022 filed this morning with the Securities and Exchange Commission.